Silexion Therapeutics Ltd.
NASDAQ Global MarketTotal Valuation
Silexion Therapeutics Ltd. carries a market capitalization of 3,366.00, placing it among publicly traded companies globally. Its enterprise value stands at -1.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3,366.00 |
| Enterprise Value | -1.77M |
Share Statistics
Silexion Therapeutics Ltd. currently has 1.18M shares outstanding.
| Shares Outstanding | 1.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Silexion Therapeutics Ltd. maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 965.91, indicating elevated leverage, while an interest coverage ratio of -1,411.50 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.94 |
| Quick Ratio | 0.56 |
| Debt / Equity | 965.91 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -1,411.50 |
Financial Efficiency
| Return on Equity (ROE) | -17,021.95 |
| Return on Assets (ROA) | -277.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Silexion Therapeutics Ltd.'s stock has declined approximately -84.49612% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -84.49612% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.11M, while operating income came in at -14.13M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -14.13M |
| Pretax Income | -13.96M |
| Net Income | -13.96M |
| EBITDA | -14.11M |
| EBIT | -14.13M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Silexion Therapeutics Ltd. holds 2.23M in cash and equivalents against 425,000.00 in total debt, resulting in a net debt position of -2.23M. Total book value stands at 44,000.00, with working capital of -235,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 2.23M |
| Total Debt | 425,000.00 |
| Net Debt | -2.23M |
| Equity (Book Value) | 44,000.00 |
| Book Value Per Share | 0.04 |
| Working Capital | -235,000.00 |
Cash Flow
Silexion Therapeutics Ltd. produced -12.43M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -2,000.00 |
| Free Cash Flow | -12.43M |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -31,298.74 |
| FCF Yield | N/A |
Scores
Silexion Therapeutics Ltd. posts an Altman Z-Score of -31.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.30 |